Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Bastian

Showing results (61-70 of 94) with videos related to

Pageof 10
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2025
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)Moritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Cancer|August 1, 1993
Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patientsH Drepper, C O Köhler, B Bastian, et al.
Cancers|August 10, 2024
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall SurvivalConnor Hein, Caroline Burgard, Arne Blickle, et al.
European Radiology Experimental|September 25, 2023
Feasibility of the chick chorioallantoic membrane model for preclinical studies on tumor radiofrequency ablationJoel Wessendorf, Michael Scheschenja, Moritz B Bastian, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model PerformanceTilman Speicher, Isa Ethem Demirkol, Arne Blickle, et al.
Pigment Cell & Melanoma Research|December 23, 2009
Melanoma from bench to bedside: meeting report from the 6th international melanoma congressD E Fisher, R Barnhill, F S Hodi, et al.
Clinical Nuclear Medicine|May 13, 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient CohortMoritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
EJNMMI Research|July 6, 2025
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopeniaMoritz B Bastian, Tilman Speicher, Arne Blickle, et al.
Clinical Nuclear Medicine|November 27, 2024
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal FunctionMoritz B Bastian, Maike Sieben, Caroline Burgard, et al.
Pageof 10

Showing results (61-70 of 94) with videos related to

Sort By:
Pageof 10
European Journal of Nuclear Medicine and Molecular Imaging|December 3, 2024
Safety of PSMA radioligand therapy in mCRPC patients with preexisting moderate to severe thrombocytopeniaMoritz B Bastian, Maike Sieben, Arne Blickle, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 26, 2025
Expanding the scope of PSMA-RLT: evaluating treatment in challenging mCRPC patients with poor performance status (ECOG 3)Moritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
Cancer|August 1, 1993
Benefit of elective lymph node dissection in subgroups of melanoma patients. Results of a multicenter study of 3616 patientsH Drepper, C O Köhler, B Bastian, et al.
Cancers|August 10, 2024
Analysis of Molecular Imaging and Laboratory Baseline Biomarkers in PSMA-RLT: Whole-Body Total Lesion PSMA (TLP) Predicts Overall SurvivalConnor Hein, Caroline Burgard, Arne Blickle, et al.
European Radiology Experimental|September 25, 2023
Feasibility of the chick chorioallantoic membrane model for preclinical studies on tumor radiofrequency ablationJoel Wessendorf, Michael Scheschenja, Moritz B Bastian, et al.
Current Oncology (Toronto, Ont.)|June 25, 2026
Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model PerformanceTilman Speicher, Isa Ethem Demirkol, Arne Blickle, et al.
Pigment Cell & Melanoma Research|December 23, 2009
Melanoma from bench to bedside: meeting report from the 6th international melanoma congressD E Fisher, R Barnhill, F S Hodi, et al.
Clinical Nuclear Medicine|May 13, 2025
PSMA Radioligand Therapy in Advanced Age: Insights From an 85y+ mCRPC Patient CohortMoritz B Bastian, Benedikt Wörl, Arne Blickle, et al.
EJNMMI Research|July 6, 2025
Tolerability of PSMA radioligand therapy in metastatic prostate cancer patients with baseline mild to moderate leukopeniaMoritz B Bastian, Tilman Speicher, Arne Blickle, et al.
Clinical Nuclear Medicine|November 27, 2024
Outcome and Renal Safety of PSMA-Targeted Radioligand Therapy in mCRPC Patients With Preexisting Impaired Renal FunctionMoritz B Bastian, Maike Sieben, Caroline Burgard, et al.
Pageof 10